For the quarter ended December 2023, QuidelOrtho (QDEL - Free Report) reported revenue of $742.6 million, down 14.3% over the same period last year. EPS came in at $1.17, compared to $1.76 in the year-ago quarter.
The reported revenue represents a surprise of -6.97% over the Zacks Consensus Estimate of $798.24 million. With the consensus EPS estimate being $2.02, the EPS surprise was -42.08%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how QuidelOrtho performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues by business unit- Molecular Diagnostics: $8.50 million versus the three-analyst average estimate of $10.05 million. The reported number represents a year-over-year change of -41.8%.
- Revenues by business unit- Point of Care: $216.80 million versus $273.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -42.1% change.
- Revenues by business unit- Transfusion Medicine: $165.40 million versus the three-analyst average estimate of $161.76 million. The reported number represents a year-over-year change of +1.8%.
- Revenues by business unit- Labs: $351.90 million versus $344.71 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +11.8% change.
View all Key Company Metrics for QuidelOrtho here>>>Shares of QuidelOrtho have returned -4.7% over the past month versus the Zacks S&P 500 composite's +5.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
For the quarter ended December 2023, QuidelOrtho (QDEL - Free Report) reported revenue of $742.6 million, down 14.3% over the same period last year. EPS came in at $1.17, compared to $1.76 in the year-ago quarter.
The reported revenue represents a surprise of -6.97% over the Zacks Consensus Estimate of $798.24 million. With the consensus EPS estimate being $2.02, the EPS surprise was -42.08%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how QuidelOrtho performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues by business unit- Molecular Diagnostics: $8.50 million versus the three-analyst average estimate of $10.05 million. The reported number represents a year-over-year change of -41.8%.
- Revenues by business unit- Point of Care: $216.80 million versus $273.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -42.1% change.
- Revenues by business unit- Transfusion Medicine: $165.40 million versus the three-analyst average estimate of $161.76 million. The reported number represents a year-over-year change of +1.8%.
- Revenues by business unit- Labs: $351.90 million versus $344.71 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +11.8% change.
View all Key Company Metrics for QuidelOrtho here>>>Shares of QuidelOrtho have returned -4.7% over the past month versus the Zacks S&P 500 composite's +5.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Get the latest research report on QDEL - FREE